Universität zu Köln

von Deimling, M., Rajwa, P., Tilki, D., Heidenreich, A., Pallauf, M., Bianchi, A., Yanagisawa, T., Kawada, T., Karakiewicz, P., I, Gontero, P., Pradere, B., Ploussard, G., Rink, M. and Shariat, S. F. (2022). The current role of precision surgery in oligometastatic prostate cancer. ESMO Open, 7 (6). AMSTERDAM: ELSEVIER. ISSN 2059-7029

Full text not available from this repository.

Abstract

Oligometastatic prostate cancer (omPCa) is a novel intermediate disease state characterized by a limited volume of metastatic cells and specific locations. Accurate staging is paramount to unmask oligometastatic disease, as provided by prostate-specific membrane antigen-positron emission tomography. Driven by the results of prospective trials employing conventional and/or modern staging modalities, the treatment landscape of omPCa has rapidly evolved over the last years. Several treatment-related questions comprising the concept of precision strikes are under development. For example, beyond systemic therapy, cohort studies have found that cytoreductive radical prostatectomy (CRP) can confer a survival benefit in select patients with omPCa. More importantly, CRP has been consistently shown to improve long-term local symptoms when the tumor progresses across disease states due to resistance to systemic therapies. Metastasis-directed treatments have also emerged as a promising treatment option due to the visibility of oligometastatic disease and new technologies as well as treatment strategies to target the novel PCa colonies. Whether metastases are present at primary cancer diagnosis or detected upon biochemical recurrence after treatment with curative intent, targeted yet decisive elimination of disseminated tumor cell hotspots is thought to improve survival outcomes. One such strategy is salvage lymph node dissection in oligorecurrent PCa which can alter the natural history of progressive PCa. In this review, we will highlight how refinements in modern staging modalities change the classification and treatment of (oligo-)metastatic PCa. Further, we will also discuss the current role and future directions of precision surgery in omPCa.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code von Deimling, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rajwa, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Tilki, D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Heidenreich, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pallauf, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bianchi, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Yanagisawa, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Kawada, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Karakiewicz, P., I UNSPECIFIED UNSPECIFIED UNSPECIFIED Gontero, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pradere, B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ploussard, G. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rink, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Shariat, S. F. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-696299
DOI:	10.1016/j.esmoop.2022.100597
Journal or Publication Title:	ESMO Open
Volume:	7
Number:	6
Date:	2022
Publisher:	ELSEVIER
Place of Publication:	AMSTERDAM
ISSN:	2059-7029
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language METASTASIS-DIRECTED THERAPY; CYTOREDUCTIVE RADICAL PROSTATECTOMY; LYMPH-NODE DISSECTION; BIOCHEMICAL RECURRENCE; ANDROGEN ABLATION; LOCAL TREATMENT; TUMOR; MEN; SURVIVAL; RADIOTHERAPY Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/69629